Articles From: UPDATE: Academy Awards winners may not reap box-office rewards to Altice Bids for Vivendi Stake in Telecom Firm--Update


2015/2/20
By Russ Britt, MarketWatch Favorites 'Birdman,' 'Boyhood' losing steam ahead of Oscars 2015 Winners will no doubt be raising their glasses after the last award is handed out at Sunday's Oscar ceremonies, but there are few expectations this year's best picture will experience anything worth toasting at the box office in coming weeks.
Sign-up for UPDATE: Academy Awards winners may not reap box-office rewards investment picks
2015/2/20
By Russ Britt, MarketWatch Favorites 'Birdman,' 'Boyhood' losing steam ahead of awards Winners will no doubt be raising their glasses after the last award is handed out at Sunday's Oscar ceremonies, but there are few expectations this year's best picture will experience anything worth toasting at the box office in coming weeks.
Sign-up for UPDATE: Box-office rewards may bypass Oscar winners investment picks
2015/2/19
By Russ Britt, MarketWatch Favorites 'Birdman,' 'Boyhood' losing steam ahead of awards Winners will no doubt be raising their glasses after the last award is handed out at Sunday's Oscar ceremonies, but there are few expectations this year's best picture will experience anything worth toasting at the box office in coming weeks.
Sign-up for Box-office rewards may bypass Oscar winners investment picks
2015/2/18
By Russ Britt, MarketWatch J&J lawsuit was 'major overhang' on stock, analysts say For much of the past decade, Boston Scientific Corp.
Sign-up for Time for Boston Scientific shares to break out? investment picks
2015/2/18
By Russ Britt, MarketWatch Retailer warns of $150 billion annual burden on health care Drug retail giant CVS Health Corp.
Sign-up for UPDATE: CVS girds for battle over cholesterol drugs investment picks
2015/2/17
By Russ Britt, MarketWatch Drug retail giant CVS Health Corp.
Sign-up for CVS Girds For Battle Over Cholesterol Drugs investment picks
2015/2/17
By Russ Britt, MarketWatch Retailer warns of $150 billion annual burden on health care Drug retail giant CVS Health Corp.
Sign-up for CVS girds for battle over cholesterol drugs investment picks
2015/2/13
By Russ Britt, MarketWatch Prana tumbles again after FDA puts hold on drug trial LOS ANGELES (MarketWatch)--Shares of drug maker GlaxoSmithKline jumped more than 4% Friday after brokerage UBS turned 180 degrees and upgraded the British multinational to "buy" from "sell." Shares of Glaxo (GSK) climbed $1.93 to $47.88 in recent action.
Sign-up for UPDATE: Broker does a 180 on Glaxo; shares surge investment picks
2015/2/13
By Russ Britt, MarketWatch Prana tumbles again after FDA puts hold on drug trial LOS ANGELES (MarketWatch)--Shares of drug maker GlaxoSmithKline jumped more than 4% Friday after brokerage UBS turned 180 degrees and upgraded the British multinational to "buy" from "sell." Shares of Glaxo (GSK) climbed $1.93 to $47.88 in recent action.
Sign-up for Broker does a 180 on Glaxo; shares surge investment picks
2015/2/12
By Russ Britt, MarketWatch Other attempts at cost control having minimal effect on system This is the last installment in a four-part series.
Sign-up for UPDATE: Health-care costs: It's time for patients to take control investment picks
2015/2/12
By Russ Britt, MarketWatch Broadcaster aims to outpace potential reunion partner Viacom With the prospect of a reunion with Viacom Inc. on the horizon, the Street will be watching to see whether CBS Corp.
Sign-up for UPDATE: What to look for in CBS earnings investment picks
2015/2/11
By Russ Britt, MarketWatch This late-night host may be exceptionally hard to replace LOS ANGELES (MarketWatch)--It's been a tumultuous 12 months for late-night talk shows, with a number of hosts playing musical chairs, but Jon Stewart's departure from "The Daily Show With Jon Stewart" could have a broader impact than most of the other recent changes.
Sign-up for UPDATE: Jon Stewart's brand building not seen since Carson investment picks
2015/2/11
By Russ Britt, MarketWatch Broadcaster aims to outpace potential reunion partner Viacom With the prospect of a reunion with Viacom Inc. on the horizon, the Street will be watching to see whether CBS Corp.
Sign-up for UPDATE: What to look for in CBS earnings investment picks
2015/2/10
By Russ Britt, MarketWatch Broadcaster aims to outpace potential reunion partner Viacom With the prospect of a reunion with Viacom Inc. on the horizon, the Street will be watching to see whether CBS Corp.
Sign-up for UPDATE: What to look for in CBS earnings investment picks
2015/2/10
By Russ Britt, MarketWatch Shares spike more than 10%; analysts cautiously optimistic LOS ANGELES (MarketWatch) -- A massive growth in enrollment, thanks largely to the expansion of Medicaid programs under Obamacare, boosted the earnings of insurer Molina Healthcare well past analyst estimates and sent the company's stock to an all-time high Tuesday.
Sign-up for Obamacare gives a lift to insurer Molina's results investment picks
2015/2/10
By Russ Britt, MarketWatch Broadcaster aims to outpace potential reunion partner Viacom With the prospect of a reunion with Viacom Inc. on the horizon, the Street will be watching to see whether CBS Corp.
Sign-up for What to look for in CBS earnings investment picks
2015/2/9
By Russ Britt, MarketWatch Shares of Regulus fall but company, analysts still see promise LOS ANGELES (MarketWatch) -- Shares of Regulus Therapeutics took it on the chin Monday after the biopharmaceutical company reported spotty results in tests for a drug designed to cure Hepatitis C with a single dose.
Sign-up for Hopes for single-dose Hepatitis C drug fade investment picks
2015/2/9
By Russ Britt, MarketWatch Broadcaster aims to outpace potential reunion partner Viacom With the prospect of a reunion with Viacom Inc. on the horizon, the Street will be watching to see whether CBS Corp.
Sign-up for What to look for in CBS earnings investment picks
2015/2/9
By Russ Britt, MarketWatch Earnings, revenue likely to come in below 2013 levels LOS ANGELES (MarketWatch)--Time Warner Inc. may be riding the success of its box-office hit "American Sniper," but the Oscar-nominated picture won't do much good when the entertainment giant reports fourth-quarter earnings on Wednesday.
Sign-up for UPDATE: 'Sniper' can't keep Time Warner from down quarter investment picks
2015/2/27
By Ruth Bender and Sam Schechner PARIS--
Sign-up for Vivendi Accepts Altice Offer to Buy 20% Numericable-SFR Stake investment picks
2015/2/18
By Ruth Bender Offer comes three months after Altice seals Numericable/SFR merger PARIS--Vivendi SA on Wednesday said Altice SA made a binding offer to buy its 20% stake in Numericable-SFR for EUR3.9 billion ($4.45 billion) Altice's EUR40 a share offer comes just three months after the group, controlled by cable tycoon Patrick Drahi, sealed the merger of its cable firm Numericable with mobile company SFR, which it bought from Vivendi in a $23 billion deal.
Sign-up for Altice bids $4.45 billion for Vivendi's stake in Numericable-SFR investment picks
2015/1/19
By Ruth Bender PARIS --
Sign-up for Societe Generale names new chairman investment picks
2015/2/18
By Ruth Bender PARIS-- Accor SA is ready to pursue more acquisitions to ramp up its digital know-how as the French hotel group tries to fight back against the growing dominance of online booking portals.
Sign-up for Accor Hopes to Counter Growing Dominance of Online Booking Portals investment picks
2015/2/12
By Ruth Bender PARIS--
Sign-up for Pernod Ricard Profit Slips, Alexandre Ricard Starts as CEO investment picks
2015/2/20
By Ruth Bender PARIS-- Danone SA on Friday said it expects its profit margin to grow slightly this year after several years of declines as the French dairy maker starts to see an improvement in its key fresh dairy business in Europe.
Sign-up for Danone Forecasts Profit Margin Growth investment picks
2015/2/17
By Ruth Bender PARIS-- Orange SA on Tuesday said it expects earnings and sales to continue to fall this year even though sales in the telecom company's intensely competitive domestic market fell less sharply than expected in the last quarter.
Sign-up for Orange Warns Sales Will Continue to Slide -- Update investment picks
2015/2/12
By Ruth Bender PARIS-- Publicis Groupe SA said Thursday it would gradually return to better growth this year as the French advertising company ended a disappointing 2014 on a slightly higher note.
Sign-up for Publicis Expects Gradual Improvement in Growth in 2015 investment picks
2015/2/18
By Ruth Bender PARIS--
Sign-up for Altice Bids for Vivendi's Stake in Numericable-SFR investment picks
2015/2/12
By Ruth Bender PARIS--As the Ricard dynasty takes back the helm of drinks group Pernod Ricard SA, its third-generation leader will face the tricky task of reviving sluggish sales in some of the company's largest markets.
Sign-up for Pernod Ricard Chief Faces Tough Test in New Role -- Update investment picks
2015/2/18
By Ruth Bender PARIS--Franco-Israeli cable tycoon Patrick Drahi is moving faster than expected toward his goal of fully controlling his newly formed telecom giant Numericable-SFR, further fueling speculation that he has other acquisitions in his sights.
Sign-up for Altice Bids for Vivendi Stake in Telecom Firm--Update investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: UPDATE: Academy Awards winners may not reap box-office rewards to Altice Bids for Vivendi Stake in Telecom Firm--Update
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent